메뉴 건너뛰기




Volumn 61, Issue 6, 2014, Pages 1228-1237

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

Author keywords

Chronic hepatitis B; Hepatitis B surface antigen; Tenofovir disoproxil fumarate

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

EID: 84922789624     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.07.019     Document Type: Article
Times cited : (90)

References (28)
  • 1
    • 84862664371 scopus 로고    scopus 로고
    • EASL Clinical Practice Guidelines: Management of chronic hepatitis B
    • European Association for the Study of the Liver
    • European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 57 2012 167 185
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 2
    • 70349240414 scopus 로고    scopus 로고
    • Chronic hepatitis B: Update 2009
    • A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
    • (2009) Hepatology , vol.50 , pp. 661-662
    • Lok, A.S.1    McMahon, B.J.2
  • 3
    • 79958038529 scopus 로고    scopus 로고
    • Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: A meta-analysis of controlled clinical trials
    • W.C. Li, M.R. Wang, L.B. Kong, W.G. Ren, Y.G. Zhang, and Y.M. Nan Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials BMC Infect Dis 11 2011 165
    • (2011) BMC Infect Dis , vol.11 , pp. 165
    • Li, W.C.1    Wang, M.R.2    Kong, L.B.3    Ren, W.G.4    Zhang, Y.G.5    Nan, Y.M.6
  • 4
    • 67349168493 scopus 로고    scopus 로고
    • High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study
    • R. Moucari, A. Korevaar, O. Lada, M. Martinot-Peignoux, N. Boyer, and V. Mackiewicz High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 2009 1084 1092
    • (2009) J Hepatol , vol.50 , pp. 1084-1092
    • Moucari, R.1    Korevaar, A.2    Lada, O.3    Martinot-Peignoux, M.4    Boyer, N.5    MacKiewicz, V.6
  • 5
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
    • (2005) N Engl J Med , vol.352 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3    Marcellin, P.4    Thongsawat, S.5    Cooksley, G.6
  • 6
    • 84873726484 scopus 로고    scopus 로고
    • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study
    • P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
    • (2013) Lancet , vol.381 , pp. 468-475
    • Marcellin, P.1    Gane, E.2    Buti, M.3    Afdhal, N.4    Sievert, W.5    Jacobson, I.M.6
  • 7
    • 57349095400 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
    • P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
    • (2008) N Engl J Med , vol.359 , pp. 2442-2455
    • Marcellin, P.1    Heathcote, E.J.2    Buti, M.3    Gane, E.4    De Man, R.A.5    Krastev, Z.6
  • 8
    • 79952227475 scopus 로고    scopus 로고
    • No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
    • A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, and J. Schawalder No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
    • (2011) Hepatology , vol.53 , pp. 763-773
    • Snow-Lampart, A.1    Chappell, B.2    Curtis, M.3    Zhu, Y.4    Myrick, F.5    Schawalder, J.6
  • 9
    • 75449107726 scopus 로고    scopus 로고
    • Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    • T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, and F.J. Carrilho Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
    • (2010) Hepatology , vol.51 , pp. 422-430
    • Chang, T.T.1    Lai, C.L.2    Kew Yoon, S.3    Lee, S.S.4    Coelho, H.S.5    Carrilho, F.J.6
  • 10
    • 84874300734 scopus 로고    scopus 로고
    • Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B
    • S.S. Kim, D. Lee, M.H. Lee, J.Y. Cheong, and S.W. Cho Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B Hepatol Res 43 2013 219 227
    • (2013) Hepatol Res , vol.43 , pp. 219-227
    • Kim, S.S.1    Lee, D.2    Lee, M.H.3    Cheong, J.Y.4    Cho, S.W.5
  • 11
    • 84890566066 scopus 로고    scopus 로고
    • Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy
    • G. Papatheodoridis, J. Goulis, S. Manolakopoulos, A. Margariti, X. Exarchos, and G. Kokkonis Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy J Hepatol 60 2014 62 68
    • (2014) J Hepatol , vol.60 , pp. 62-68
    • Papatheodoridis, G.1    Goulis, J.2    Manolakopoulos, S.3    Margariti, A.4    Exarchos, X.5    Kokkonis, G.6
  • 12
    • 79960124298 scopus 로고    scopus 로고
    • Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss
    • R. Zoutendijk, B.E. Hansen, A.J. van Vuuren, C.A. Boucher, and H.L. Janssen Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss J Infect Dis 204 2011 415 418
    • (2011) J Infect Dis , vol.204 , pp. 415-418
    • Zoutendijk, R.1    Hansen, B.E.2    Van Vuuren, A.J.3    Boucher, C.A.4    Janssen, H.L.5
  • 13
    • 84875279880 scopus 로고    scopus 로고
    • Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
    • P. Marcellin, F. Bonino, C. Yurdaydin, S. Hadziyannis, R. Moucari, and H.P. Kapprell Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients Hepatol Int 7 2013 88 97
    • (2013) Hepatol Int , vol.7 , pp. 88-97
    • Marcellin, P.1    Bonino, F.2    Yurdaydin, C.3    Hadziyannis, S.4    Moucari, R.5    Kapprell, H.P.6
  • 14
    • 84922773840 scopus 로고    scopus 로고
    • A finite course of peginterferon alfa-2a results in inactive chronic hepatitis B and HBsAg clearance 5 years post-treatment in patients with HBeAg-negative disease: Baseline characteristics and predictive factors of long-term response
    • October 30-November 3 Boston, MA
    • Marcellin P, Piratvisuth T, Brunetto MR, Bonino F, Farci P, Yurdaydin C, et al. A finite course of peginterferon alfa-2a results in inactive chronic hepatitis B and HBsAg clearance 5 years post-treatment in patients with HBeAg-negative disease: baseline characteristics and predictive factors of long-term response. In: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30-November 3, 2009; Boston, MA.
    • (2009) 60th Annual Meeting of the American Association for the Study of Liver Diseases
    • Marcellin, P.1    Piratvisuth, T.2    Brunetto, M.R.3    Bonino, F.4    Farci, P.5    Yurdaydin, C.6
  • 15
    • 84856203453 scopus 로고    scopus 로고
    • Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: Relation to response and HBV genotype
    • M.J. Sonneveld, V. Rijckborst, Y. Cakaloglu, K. Simon, E.J. Heathcote, and F. Tabak Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype Antivir Ther 17 2012 9 17
    • (2012) Antivir Ther , vol.17 , pp. 9-17
    • Sonneveld, M.J.1    Rijckborst, V.2    Cakaloglu, Y.3    Simon, K.4    Heathcote, E.J.5    Tabak, F.6
  • 16
    • 77956592924 scopus 로고    scopus 로고
    • Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients
    • K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
    • (2010) Hepatology , vol.52 , pp. 1611-1620
    • Wursthorn, K.1    Jung, M.2    Riva, A.3    Goodman, Z.D.4    Lopez, P.5    Bao, W.6
  • 17
    • 80055059164 scopus 로고    scopus 로고
    • Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
    • Y.F. Liaw, J.D. Jia, H.L. Chan, K.H. Han, T. Tanwandee, and W.L. Chuang Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C Hepatology 54 2011 1591 1599
    • (2011) Hepatology , vol.54 , pp. 1591-1599
    • Liaw, Y.F.1    Jia, J.D.2    Chan, H.L.3    Han, K.H.4    Tanwandee, T.5    Chuang, W.L.6
  • 18
    • 43149102738 scopus 로고    scopus 로고
    • Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in the Gambia
    • M.E. Mendy, S.J. McConkey, M.A. van der Sande, S. Crozier, S. Kaye, and D. Jeffries Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia Virol J 5 2008 49
    • (2008) Virol J , vol.5 , pp. 49
    • Mendy, M.E.1    McConkey, S.J.2    Van Der Sande, M.A.3    Crozier, S.4    Kaye, S.5    Jeffries, D.6
  • 19
    • 0026580185 scopus 로고
    • Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B
    • M.A. Loriot, P. Marcellin, E. Bismuth, M. Martinot-Peignoux, N. Boyer, and C. Degott Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B Hepatology 15 1992 32 36
    • (1992) Hepatology , vol.15 , pp. 32-36
    • Loriot, M.A.1    Marcellin, P.2    Bismuth, E.3    Martinot-Peignoux, M.4    Boyer, N.5    Degott, C.6
  • 20
    • 0025156837 scopus 로고
    • Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy
    • P. Marcellin, M. Martinot-Peignoux, M.A. Loriot, E. Giostra, N. Boyer, and V. Thiers Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy Ann Intern Med 112 1990 227 228
    • (1990) Ann Intern Med , vol.112 , pp. 227-228
    • Marcellin, P.1    Martinot-Peignoux, M.2    Loriot, M.A.3    Giostra, E.4    Boyer, N.5    Thiers, V.6
  • 21
    • 73449089431 scopus 로고    scopus 로고
    • Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    • R. Moucari, M. Martinot-Peignoux, V. Mackiewicz, N. Boyer, M.P. Ripault, and C. Castelnau Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a Antivir Ther 14 2009 1183 1188
    • (2009) Antivir Ther , vol.14 , pp. 1183-1188
    • Moucari, R.1    Martinot-Peignoux, M.2    MacKiewicz, V.3    Boyer, N.4    Ripault, M.P.5    Castelnau, C.6
  • 22
    • 44949180106 scopus 로고    scopus 로고
    • Understanding the immunopathogenesis of chronic hepatitis B virus: An Asian prospective
    • A.T. Tan, S. Koh, V. Goh, and A. Bertoletti Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective J Gastroenterol Hepatol 23 2008 833 843
    • (2008) J Gastroenterol Hepatol , vol.23 , pp. 833-843
    • Tan, A.T.1    Koh, S.2    Goh, V.3    Bertoletti, A.4
  • 23
    • 4544239807 scopus 로고    scopus 로고
    • Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    • P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
    • (2004) N Engl J Med , vol.351 , pp. 1206-1217
    • Marcellin, P.1    Lau, G.K.2    Bonino, F.3    Farci, P.4    Hadziyannis, S.5    Jin, R.6
  • 25
    • 72949113706 scopus 로고    scopus 로고
    • Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
    • R.G. Gish, T.T. Chang, C.L. Lai, R. de Man, A. Gadano, and F. Poordad Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B J Viral Hepat 17 2010 16 22
    • (2010) J Viral Hepat , vol.17 , pp. 16-22
    • Gish, R.G.1    Chang, T.T.2    Lai, C.L.3    De Man, R.4    Gadano, A.5    Poordad, F.6
  • 26
    • 48549107919 scopus 로고    scopus 로고
    • Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
    • E.H. Buster, H.J. Flink, Y. Cakaloglu, K. Simon, J. Trojan, and F. Tabak Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
    • (2008) Gastroenterology , vol.135 , pp. 459-467
    • Buster, E.H.1    Flink, H.J.2    Cakaloglu, Y.3    Simon, K.4    Trojan, J.5    Tabak, F.6
  • 27
    • 79955093993 scopus 로고    scopus 로고
    • Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
    • J.M. Lee, S.H. Ahn, H.S. Kim, H. Park, H.Y. Chang, and Y. Kim Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir Hepatology 53 2011 1486 1493
    • (2011) Hepatology , vol.53 , pp. 1486-1493
    • Lee, J.M.1    Ahn, S.H.2    Kim, H.S.3    Park, H.4    Chang, H.Y.5    Kim, Y.6
  • 28
    • 65449123444 scopus 로고    scopus 로고
    • Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    • R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Martinot-Peignoux Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
    • (2009) Hepatology , vol.49 , pp. 1151-1157
    • Moucari, R.1    MacKiewicz, V.2    Lada, O.3    Ripault, M.P.4    Castelnau, C.5    Martinot-Peignoux, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.